Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
You may also be interested in...
The latest oncology development news and highlights from our US FDA Performance Tracker.
Update of 2007 guidance includes discussion on use of newer endpoints and clarifies that oncology endpoints can serve different purposes.
Amgen sees the approval as a platform to expand blinatumomab into other hematologic malignancies using similar approaches.